COVID-19, hypercoagulation and what it could mean for patients with psychotic disorders

Mongan, David; Cannon, Mary; Cotter, David

doi:10.1016/j.bbi.2020.05.067

Cited by 10 publications

(20 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Supplementary Table 1 available at provides a summary of characteristics of the included studies in this review. 2,4-50…”

Section: Resultsmentioning

confidence: 99%

“…As such, it is hypothesised that patients with SSD who contract COVID-19 may be at higher risk of thrombotic complications, considering that both illnesses increase such risk. 10…”

Section: Resultsmentioning

confidence: 99%

“…2 Higher risk of coagulopathy is another consideration for patients with SSD who acquire COVID-19 infection. 10 COVID-19 has been associated with hypercoagulation, and current guidelines recommend routine use of thromboprophylaxis in patients with COVID-19 infection. At the same time, patients with SSD have been reported to have a two-to three-fold increased risk of deep vein thrombosis or pulmonary embolism, 51 likely multifactorial in nature, including biological dysregulation of the illness itself, medications and lifestyle.…”

Section: Risk Factors For Covid-19 Infection and Poorer Outcomementioning

confidence: 99%

“…As such, it is hypothesised that patients with SSD who contract COVID-19 may be at higher risk of thrombotic complications, considering that both illnesses increase such risk. 10 In addition to health risks related to COVID-19 infection in patients with SSD, there is concern about worsening of underlying medical conditions as a result of lack of access during the pandemic. 11 In general, patients with SMI, including patients with SSD, have high rates of chronic medical comorbidities and higher rates of undertreated conditions compared with the general population.…”

Section: Risk Factors For Covid-19 Infection and Poorer Outcomementioning

confidence: 99%

See 3 more Smart Citations

Implications of the COVID-19 pandemic for patients with schizophrenia spectrum disorders: narrative review

Zhand

Joober

2021

BJPsych open

View full text Add to dashboard Cite

Background COVID-19 was declared a pandemic in March 2020, by the World Health Organization. The pandemic has had unprecedented worldwide implications, in particular on marginalized populations. Aims The aim of this study is to review the impact of the pandemic on patients with schizophrenia spectrum disorders. Method A number of databases were searched for this review, including PubMed, EMBASE, PsycINFO and Google Scholar. Search terms included psychosis and COVID-19, schizophrenia and COVID-19, and severe mental illness and COVID-19. We included all English language papers and preprints. The final search was done on 15 July 2020. Results Forty-seven relevant studies were identified and included in this review. Studies were summarised into five main subcategories: potential impact of the COVID-19 pandemic on physical health outcomes of patients with schizophrenia spectrum disorders, impact on mental health outcomes, review of case reports and case series to date, treatment recommendation guidelines and risk of increased prevalence of psychosis. Conclusions Patients with schizophrenia spectrum disorders may be vulnerable to the effects of the COVID-19 pandemic. This patient population has a number of risk factors, including psychosocial adversities and illness related factors. Continuous monitoring and long-term studies of the impact of the pandemic on this patient population are required.

show abstract

“…Supplementary Table 1 available at provides a summary of characteristics of the included studies in this review. 2,4-50…”

Section: Resultsmentioning

confidence: 99%

“…As such, it is hypothesised that patients with SSD who contract COVID-19 may be at higher risk of thrombotic complications, considering that both illnesses increase such risk. 10…”

Section: Resultsmentioning

confidence: 99%

Section: Risk Factors For Covid-19 Infection and Poorer Outcomementioning

confidence: 99%

Section: Risk Factors For Covid-19 Infection and Poorer Outcomementioning

confidence: 99%

See 2 more Smart Citations

Implications of the COVID-19 pandemic for patients with schizophrenia spectrum disorders: narrative review

Zhand

Joober

2021

BJPsych open

View full text Add to dashboard Cite

show abstract

“…Of particular interest are studies which have identified abnormalities consistent with hypercoagulability in patients with psychosis, and proteomic evidence which suggests complement activation and hypercoagulation may precede psychosis in the general population. 15 Although such evidence is limited, if associations between coagulation abnormalities and psychosis are rigorously established, hypercoagulability may represent a plausible mechanism by which COVID-19 mediates its neuropsychiatric sequelae.…”

Section: Discussionmentioning

confidence: 99%

Severe psychiatric disturbance and attempted suicide in a patient with COVID-19 and no psychiatric history

Gillett

Jordan

2020

BMJ Case Rep

View full text Add to dashboard Cite

A previously fit and well 37-year-old male healthcare worker presented with confusion, psychotic symptoms and a suicide attempt in the context of a new COVID-19 diagnosis. Following surgical interventions and an extended admission to the intensive care unit, he made a good recovery in terms of both his physical and mental health. A number of factors likely contributed to his presentation, including SARS-CoV-2 infection, severe insomnia, worry, healthcare worker-related stress, and the unique social and psychological stressors associated with the COVID-19 pandemic. This case highlights the need to further characterise the specific psychiatric sequelae of COVID-19 in community settings, and should remind general medical clinicians to be mindful of comorbid psychiatric symptoms when assessing patients with newly diagnosed COVID-19.

show abstract

The three frontlines against COVID-19: Brain, Behavior, and Immunity

Wang

Pariante

2021

Brain, Behavior, and Immunity

View full text Add to dashboard Cite

The pandemic outbreak of coronavirus disease 2019 (COVID-19) is raising global anxiety and fear of both real and perceived health threat from the virus. Overwhelming evidence shows infected patients experiencing neuropsychiatric complications, suggesting that the “psychoneuroimmunity” model might be beneficial in understanding the impact of the virus. Therefore, this Special Issue on “Immunopsychiatry of COVID-19 Pandemic” was launched immediately after the pandemic was declared, with the first paper accepted on the March 25 th , 2020. A total of ninety-three papers were accepted, the last one was on the July 10 th , 2020 when the initial acute phase started declining. The papers of this Special Issue have illuminated the social impact, psychopathology, neurological manifestation, immunity responses, and potential treatments and prevention on COVID-19. For example, anxiety disorders, mood disorders, and suicidal ideation are most common psychiatric manifestations. COVID-19 infection can have central and/or peripheral nervous system symptoms, including headache, sleep disorders, encephalopathy, and loss of taste and smell. A “three-steps” Neuro-COVID infection model (neuro-invasion, clearance and immune response) was established. The current therapeutic interventions for COVID-19 include supportive intervention, immunomodulatory agents, antiviral therapy, and plasma transfusion. Psychological support should be implemented, improving the psychological wellbeing, as well as to enhance psychoneuroimmunity against COVID-19.

show abstract

COVID-19, hypercoagulation and what it could mean for patients with psychotic disorders

Cited by 10 publications

References 11 publications

Implications of the COVID-19 pandemic for patients with schizophrenia spectrum disorders: narrative review

Implications of the COVID-19 pandemic for patients with schizophrenia spectrum disorders: narrative review

Severe psychiatric disturbance and attempted suicide in a patient with COVID-19 and no psychiatric history

The three frontlines against COVID-19: Brain, Behavior, and Immunity

Contact Info

Product

Resources

About